WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202590
CAS#: 164301-51-3 (HCl)
Description: Semapimod, known as CNI-1493, is a cytokine inhibitor. Semapimod is an investigational new drug which has anti-inflammatory, anti-cytokine, immunomodulatory, antiviral and antimalarial properties. Structurally, semapimod is synthetic guanylhydrazone mitogen-activated protein kinase blocker, as a potential treatment for Crohn's disease and other inflammatory conditions.
MedKoo Cat#: 202590
Name: Semapimod hydrochloride
CAS#: 164301-51-3 (HCl)
Chemical Formula: C34H52N18O2
Exact Mass: 744.45206
Molecular Weight: 744.9
Elemental Analysis: C, 54.82; H, 7.04; N, 33.85; O, 4.30
Semapimod hydrochloride, purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).
Related CAS #: 164301-51-3 (HCl) 352513-83-8 (free base) 872830-76-7 (HCl hydrate) 872830-80-3 (mesylate)
Synonym: CNI1493; CNI-1493; CNI1493; AXD-455; AXD 455; AXD455; AIDS121302; AIDS-121302; Semapimod HCl.
IUPAC/Chemical Name: N1,N10-bis(3-(1-(2-carbamimidoylhydrazono)ethyl)-5-(1-(2-carbamimidoylhydrazono)ethyl)phenyl)decanediamide, tetrahydrochloride
InChi Key: MAHASPGBAIQZLY-RTQZJKMDSA-N
InChi Code: InChI=1S/C34H52N18O2.4ClH/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42;;;;/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52);4*1H/b45-19+,46-20+,47-21+,48-22+;;;;
SMILES Code: O=C(NC1=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C1)CCCCCCCCC(NC2=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C2)=O.[H]Cl.[H]Cl.[H]Cl.[H]Cl
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in water | 100.0 |
The following data is based on the product molecular weight 744.9 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Miller IS, Didier S, Murray DW, Turner TH, Issaivanan M, Ruggieri R, Al-Abed Y, Symons M. Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS One. 2014 May 9;9(5):e95885. doi: 10.1371/journal.pone.0095885. eCollection 2014. PubMed PMID: 24816734; PubMed Central PMCID: PMC4015930.
2: Erin N, Duymuş O, Oztürk S, Demir N. Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis. Regul Pept. 2012 Nov 10;179(1-3):101-8. doi: 10.1016/j.regpep.2012.08.001. Epub 2012 Sep 11. PubMed PMID: 22982142.
3: Vlachakis IK, Pitoulias GA, Kontopoulou KE, Kotakidou RE, Kosmidou EK, Kallaitzopoulou ME, Papadimitriou DK. Semapimod a new pretreatment modality of acute intestinal ischemia-reperfusion syndrome: experimental study in rabbits. Int Angiol. 2011 Feb;30(1):35-42. PubMed PMID: 21248671.
4: Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut. 2010 Jun;59(6):760-6. doi: 10.1136/gut.2009.179994. PubMed PMID: 20551461.
5: de Jonge WJ, The FO, Löwenberg M, Boeckxstaens GE. P38 MAPK inhibitor semapimod reduces postoperative ileus via peripheral and central mechanisms. Gastroenterology. 2009 May;136(5):1841-2; author reply 1842. doi: 10.1053/j.gastro.2008.12.075. Epub 2009 Mar 18. PubMed PMID: 19303016.
6: van Westerloo DJ, Rauws EA, Hommes D, de Vos AF, van der Poll T, Powers BL, Fockens P, Dijkgraaf MG, Bruno MJ. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc. 2008 Aug;68(2):246-54. doi: 10.1016/j.gie.2008.01.034. Epub 2008 May 2. PubMed PMID: 18455169.
7: Singer AJ, McClain SA, Hacht G, Batchkina G, Simon M. Semapimod reduces the depth of injury resulting in enhanced re-epithelialization of partial-thickness burns in swine. J Burn Care Res. 2006 Jan-Feb;27(1):40-9. PubMed PMID: 16566536.
8: Löwenberg M, Verhaar A, van den Blink B, ten Kate F, van Deventer S, Peppelenbosch M, Hommes D. Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300. PubMed PMID: 16081798.
9: Zamora R, Grishin A, Wong C, Boyle P, Wang J, Hackam D, Upperman JS, Tracey KJ, Ford HR. High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G643-52. Epub 2005 Jun 9. PubMed PMID: 15947118.
10: Kherani AR, Moss GW, Zhou H, Gu A, Zhang G, Schulman AR, Fal JM, Sorabella R, Plasse T, Rui L, Homma S, Burkhoff D, Oz MC, Wang J. Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure. J Cardiovasc Pharmacol. 2004 Dec;44(6):665-71. PubMed PMID: 15550785.
11: Sitaraman SV, Hoteit M, Gewirtz AT. Semapimod. Cytokine. Curr Opin Investig Drugs. 2003 Nov;4(11):1363-8. Review. PubMed PMID: 14758776.
Related CAS#
CAS#164301-51-3 (Semapimod HCl).
CAS#352513-83-8 (Semapimod free base).
